NUVBNuvation Bio Inc.
Pharmaceutical Preparations
- Revenue
- $63M
- 699% YoY
- Operating margin
- -338.7%
- 96% YoY
- EBITDA
- −$211M
- 64% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$16M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired57% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $8M | $63M | 699% |
| Operating income | −$93M | −$120M | −$100M | −$593M | −$213M | 64% |
| Net income | −$87M | −$104M | −$76M | −$568M | −$205M | 64% |
| Operating cash flow | −$68M | −$96M | −$68M | −$130M | −$173M | 33% |
| Stock-based comp | $9M | $16M | $20M | $32M | $36M | 11% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $28M | 77 | — |
| FY2024 | $4M | $7M | 23 | — |
| FY2023 | $4M | $3M | 13 | — |